Last reviewed · How we verify
Allo-QuadCAR01-T — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Allo-QuadCAR01-T (Allo-QuadCAR01-T) — AvenCell Therapeutics, Inc.. Allogeneic CAR-T cells engineered to target four tumor-associated antigens simultaneously for enhanced cancer cell recognition and elimination.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Allo-QuadCAR01-T TARGET | Allo-QuadCAR01-T | AvenCell Therapeutics, Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Allo-QuadCAR01-T CI watch — RSS
- Allo-QuadCAR01-T CI watch — Atom
- Allo-QuadCAR01-T CI watch — JSON
- Allo-QuadCAR01-T alone — RSS
Cite this brief
Drug Landscape (2026). Allo-QuadCAR01-T — Competitive Intelligence Brief. https://druglandscape.com/ci/allo-quadcar01-t. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing